ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 632

IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy

Helen Benham1, Linda Rehaume1, Athan Baillet1, Zaied Bhuyan1, Jaclyn Bowman1, Dimeng Pang1, Kristine Kikly2, Geoffrey Strutton3, Matthew Brown1 and Ranjeny Thomas1, 1University of Queensland Diamantina Institute, Brisbane, Australia, 2Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, 3Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: IL-23, psoriasis, spondylarthritis and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose

Psoriasis (Ps) is a common immune-mediated inflammatory skin disease and is a well- recognised extra-articular manifestation of the spondyloathopathies (SpA).  Genetic studies implicate IL-23 signalling in the pathogenesis of both Ps and SpA. Spondyloarthritis and psoriasis-like disease develop in an IL-23-dependent fashion in ZAP70-mutant SKG mice, which have deficient T cell receptor signaling. We characterized curdlan (1,3-D β-glucan) induced psoriasis-like inflammation in SKG mice, investigating the role of IL-23, IL-22/IL-17, regulatory  T cells (Tregs) and microbiota.

Methods

SKG mice, IL-17A-deficient SKG mice, Germ Free SKG mice and Foxp3-DTR SKG mice were injected intraperitoneally with curdlan (1,3-D β-glucan) to induce disease. Anti-mouse IL-22, anti-IL-23 or isotype control antibodies were given i.p one day before curdlan, and weekly until sacrifice. Recombinant IL-23 or PBS was administered intra-dermally into ear skin. Outcomes were measured by clinical and histological scoring; cytokines and by qRT-PCR and in supernatants of cultured tissue explants by ELISA and CBA.

Results

Curdlan induced psoriasis-like inflammation in addition to spondyloarthritis in 100% of SKG mice. SKG skin lesions showed a histological phenotype similar to human Ps with elevated constitutive levels of IL-23a(p19) and increased secretion of both IL-17 and IL-22, 7 days after curdlan. Neutralisation of both IL-23 and IL-22 suppressed development of skin inflammation, in contrast IL-17A-deficient SKG mice were only partially spared. Germ Free (GF) SKG mice failed to develop significant skin inflammation after curdlan, however colonization of GF-SKG mice with a limited microbiota induced mild psoriasis-like inflammation. Tregs modulated the severity of skin inflammation through the suppression of IL-23 secretion. Intradermal injection of IL-23 induced IL-22 mediated, microbiota dependent psoriasis-like inflammation in naïve SKG mice.

Conclusion

In curdlan-treated SKG mice IL-23-driven psoriasis-like inflammation is induced in the setting of spondyloarthritis. The skin inflammation recapitulates several features of human Ps and is dependent on the relative contributions of IL-17, IL-22, microbiota and the balance of Tregs and T effector cells.


Disclosure:

H. Benham,
None;

L. Rehaume,
None;

A. Baillet,
None;

Z. Bhuyan,
None;

J. Bowman,
None;

D. Pang,
None;

K. Kikly,
None;

G. Strutton,
None;

M. Brown,
None;

R. Thomas,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-23-mediates-psoriasis-like-inflammation-in-the-skg-mouse-model-of-spondyloarthropathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology